[go: up one dir, main page]

PL2514750T3 - Tiazolilodihydropirymidyny podstawione bromofenylem - Google Patents

Tiazolilodihydropirymidyny podstawione bromofenylem

Info

Publication number
PL2514750T3
PL2514750T3 PL12176861T PL12176861T PL2514750T3 PL 2514750 T3 PL2514750 T3 PL 2514750T3 PL 12176861 T PL12176861 T PL 12176861T PL 12176861 T PL12176861 T PL 12176861T PL 2514750 T3 PL2514750 T3 PL 2514750T3
Authority
PL
Poland
Prior art keywords
bromo
phenyl substituted
substituted thiazolyl
dihydropyrimidines
thiazolyl dihydropyrimidines
Prior art date
Application number
PL12176861T
Other languages
English (en)
Inventor
Siegfried Goldmann
Jing Li
Yisong Liu
Original Assignee
Ruyuan Wei Xiang Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40155886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2514750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ruyuan Wei Xiang Tech Co Ltd filed Critical Ruyuan Wei Xiang Tech Co Ltd
Publication of PL2514750T3 publication Critical patent/PL2514750T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12176861T 2007-06-18 2008-06-18 Tiazolilodihydropirymidyny podstawione bromofenylem PL2514750T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710119019 2007-06-18
EP08757463A EP2159224B1 (en) 2007-06-18 2008-06-18 Bromo-phenyl substituted thiazolyl dihydropyrimidines
EP12176861.8A EP2514750B1 (en) 2007-06-18 2008-06-18 Bromo-phenyl substituted thiazolyl dihydropyrimidines

Publications (1)

Publication Number Publication Date
PL2514750T3 true PL2514750T3 (pl) 2014-05-30

Family

ID=40155886

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08757463T PL2159224T3 (pl) 2007-06-18 2008-06-18 Tiazolilohydropirymidyny podstawione bromofenylem
PL12176861T PL2514750T3 (pl) 2007-06-18 2008-06-18 Tiazolilodihydropirymidyny podstawione bromofenylem

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08757463T PL2159224T3 (pl) 2007-06-18 2008-06-18 Tiazolilohydropirymidyny podstawione bromofenylem

Country Status (14)

Country Link
US (4) US8236797B2 (pl)
EP (2) EP2514750B1 (pl)
JP (2) JP5361879B2 (pl)
KR (1) KR101173892B1 (pl)
CN (2) CN101328171A (pl)
AU (1) AU2008265397C1 (pl)
BR (1) BRPI0813237B8 (pl)
CA (1) CA2691056C (pl)
DK (2) DK2159224T3 (pl)
ES (2) ES2442907T3 (pl)
PL (2) PL2159224T3 (pl)
PT (2) PT2159224E (pl)
RU (1) RU2443703C2 (pl)
WO (1) WO2008154817A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514750B1 (en) 2007-06-18 2013-11-20 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
CN101575318B (zh) * 2009-06-25 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途
JP6162144B2 (ja) * 2012-01-06 2017-07-19 ヤンセン・サイエンシズ・アイルランド・ユーシー ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TWI668217B (zh) * 2012-08-24 2019-08-11 廣東東陽光藥業有限公司 二氫嘧啶類化合物及其在藥物中的應用
CN103664897B (zh) * 2012-09-01 2018-04-03 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN103664925B (zh) * 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
HK1210152A1 (en) * 2012-09-10 2016-04-15 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CN104945394B (zh) * 2012-09-27 2017-12-05 广东东阳光药业有限公司 二氢嘧啶衍生物的晶型
WO2014153459A2 (en) * 2013-03-20 2014-09-25 Indiana University Research And Technology Corporation Fluorescent-hap: a diagnostic stain for hbv cores in cells
US9498479B2 (en) 2013-11-19 2016-11-22 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
US9643962B2 (en) * 2013-11-27 2017-05-09 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
AU2015236982B2 (en) * 2014-03-28 2017-12-14 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
EP3139954A4 (en) * 2014-05-09 2018-02-28 Indiana University Research and Technology Corporation Methods and compositions for treating hepatitis b virus infections
RU2017127611A (ru) 2015-02-07 2019-03-07 Саншайн Лейк Фарма Ко., Лтд. Комплексные соединения и соли производных дигидропиримидина и их применение в фармацевтических препаратах
MX377531B (es) 2015-11-03 2025-03-10 Hoffmann La Roche Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
EP3503894A1 (en) 2016-08-24 2019-07-03 H. Hoffnabb-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
LT3587420T (lt) 2017-02-23 2021-07-12 Fujian Cosunter Pharmaceutical Co., Ltd. Triciklis junginys ir jo naudojimas
JP6813665B2 (ja) * 2017-03-31 2021-01-13 富士フイルム株式会社 ４−ピリドン化合物またはその塩、それを含む医薬組成物および剤
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
CN107501257B (zh) * 2017-08-17 2020-05-29 山东大学 二氢嘧啶-三氮唑类衍生物及其制备方法与应用
CA3101373A1 (en) 2018-05-25 2019-11-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
EP3854797B1 (en) 2018-08-23 2023-03-15 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of tri-cycle compound and application thereof
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CN114728973B (zh) 2019-11-22 2024-06-28 正大天晴药业集团股份有限公司 一种核蛋白抑制剂的晶型及其应用
WO2022166923A1 (zh) 2021-02-05 2022-08-11 和博医药有限公司 苯基二氢嘧啶类化合物及其应用
WO2022268154A1 (zh) * 2021-06-24 2022-12-29 上海齐鲁制药研究中心有限公司 新型抗乙肝化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE3234684A1 (de) * 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5340816A (en) 1990-10-18 1994-08-23 E. R. Squibb & Sons, Inc. Hydroxymethyl(methylenecyclopentyl) purines and pyrimidines
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5753789A (en) 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO1998009964A1 (en) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
WO1998033501A1 (en) 1997-01-31 1998-08-06 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
TW434252B (en) 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
DE19817262A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
DE19817264A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
US6636943B1 (en) * 1999-07-30 2003-10-21 Hewlett-Packard Development Company, L.P. Method for detecting continuity modules in a direct Rambus DRAM subsystem
WO2001045712A1 (de) 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
SE0001836D0 (sv) 2000-05-18 2000-05-18 Inovacor Ab Computer based system
US20070091437A1 (en) 2003-07-22 2007-04-26 Sumitomo Chemical Company, Limited Reflective polarizer, laminated optical member, and liquid crystal display apparatus
CN101104617B (zh) 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) * 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101225084A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328169B (zh) 2007-06-18 2011-05-25 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
EP2514750B1 (en) 2007-06-18 2013-11-20 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2008154820A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy

Also Published As

Publication number Publication date
ES2442907T3 (es) 2014-02-14
JP2013231036A (ja) 2013-11-14
DK2514750T3 (da) 2013-12-02
JP5970421B2 (ja) 2016-08-17
JP2010530374A (ja) 2010-09-09
BRPI0813237A2 (pt) 2014-12-23
EP2514750A1 (en) 2012-10-24
ES2391597T3 (es) 2012-11-28
DK2514750T5 (en) 2014-02-17
CA2691056A1 (en) 2008-12-24
PL2159224T3 (pl) 2012-12-31
US8236797B2 (en) 2012-08-07
CN102066369B (zh) 2013-05-29
PT2514750E (pt) 2014-01-23
USRE45004E1 (en) 2014-07-08
AU2008265397A1 (en) 2008-12-24
US20100240655A1 (en) 2010-09-23
EP2159224B1 (en) 2012-08-01
EP2159224A4 (en) 2011-08-03
EP2514750B1 (en) 2013-11-20
USRE44987E1 (en) 2014-07-01
PT2159224E (pt) 2012-10-24
AU2008265397B2 (en) 2011-07-21
CN102066369A (zh) 2011-05-18
JP5361879B2 (ja) 2013-12-04
AU2008265397B9 (en) 2011-08-04
RU2443703C2 (ru) 2012-02-27
EP2159224A1 (en) 2010-03-03
DK2159224T3 (da) 2012-08-20
BRPI0813237B1 (pt) 2020-01-07
US8343969B2 (en) 2013-01-01
AU2008265397C1 (en) 2013-08-29
KR20100038104A (ko) 2010-04-12
CN101328171A (zh) 2008-12-24
HK1174035A1 (en) 2013-05-31
RU2010101212A (ru) 2011-07-27
US20120282221A1 (en) 2012-11-08
CA2691056C (en) 2014-03-11
KR101173892B1 (ko) 2012-08-16
BRPI0813237B8 (pt) 2021-05-25
WO2008154817A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
PL2514750T3 (pl) Tiazolilodihydropirymidyny podstawione bromofenylem
IL185609A0 (en) Multi function senssor
GB0808486D0 (en) Phtovoltaic tile assembly
EP2352801A4 (en) ELECTROACTIVE MATERIALS
GB2455700B (en) Bolus
GB2455986B (en) Retaining formation
EP2352802A4 (en) ELECTROACTIVE MATERIALS
LT2203612T (lt) Stogo elementas
HUE055410T2 (hu) Ütközõelem
SI2031168T1 (sl) Odbojni element
GB0702689D0 (en) Touchpad
PL2250325T3 (pl) Element budowlany
GB0714315D0 (en) Building element
GB0715902D0 (en) Flooring
GB0701936D0 (en) Building element
GB2445357B (en) Construction element
GB0720238D0 (en) Improved blind
KG1098C1 (en) Towel-drying construction
GB0717492D0 (en) Turn case
PL2019176T3 (pl) Element mocujący
GB2450151B (en) Kiln
GB0709404D0 (en) Sanitiser
HU0600006D0 (en) Flooring element
GB0713145D0 (en) Photoluminous compound stone
GB0718979D0 (en) Bricks